trial · primary record
Lurbinectedin
Desmoplastic Small Round Cell Tumor
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2030-10-01 |
| Primary endpoint | Overall tumour Response Rate (ORR), according to RECIST v 1.1 |
| Registry ID | NCT07328425 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:54.303Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07328425
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Lurbinectedin · approval
- Lurbinectedin · compound